Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 4/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306546 | 0.92 | TAS1R3 (0.34) | L3MBTL1MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL6313748 | 0.92 | SMN1; SMN2 (0.33) | L3MBTL1MAPTGAALMNAHSD17B10 | |
| SCHEMBL6306456 | 0.91 | FDPS (0.34) | SLC5A2MAPTGAAKDM4EUSP2 | |
| SCHEMBL6326005 | 0.90 | L3MBTL1 (0.32) | L3MBTL1SLC5A2MAPTGAAKDM4E | |
| SCHEMBL6313922 | 0.88 | MAPT (0.33) | SLC5A2MAPTGAAKDM4EUSP2 | |
| SCHEMBL6258332 | 0.86 | MAPT (0.31) | MAPTGAAKDM4EUSP2LMNA | |
| SCHEMBL6306343 | 0.86 | L3MBTL1 (0.37) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6306683 | 0.85 | CA12 (0.37) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6253453 | 0.85 | FDPS (0.36) | SLC5A2MAPTGAAKDM4EUSP2 | |
| SCHEMBL6428834 | 0.85 | L3MBTL1 (0.33) | L3MBTL1SLC5A2MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | claimed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | claimed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | claimed |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | ILEX PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | PHAN HIEU TRUNG (CH) | 2003-06-19 | — | — | US | disclosed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | L3MBTL1 748/4885CA12 4666/4885CA1 4697/4885 |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | L3MBTL1 748/4885CA12 4666/4885CA1 4697/4885 |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | APOB, LDLR, HDLBP | L3MBTL1 1294/4885CA12 4875/4885CA1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.